APA (7th ed.) Citation

Digomann, D., Heiduk, M., Reiche, C., Glück, J., Kahlert, C., Mirtschink, P., . . . Seifert, A. (2023). Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. npj precision oncology, 7, . https://doi.org/10.1038/s41698-023-00459-9

Chicago Style (17th ed.) Citation

Digomann, David, et al. "Serum Immune Checkpoint Profiling Identifies Soluble CD40 as a Biomarker for Pancreatic Cancer." Npj Precision Oncology 7 (2023). https://doi.org/10.1038/s41698-023-00459-9.

MLA (9th ed.) Citation

Digomann, David, et al. "Serum Immune Checkpoint Profiling Identifies Soluble CD40 as a Biomarker for Pancreatic Cancer." Npj Precision Oncology, vol. 7, 2023, https://doi.org/10.1038/s41698-023-00459-9.